VERAXA Biotech AG Secures Shareholder Approval for Merger, Eyes NASDAQ Listing

Zurich, March 3, 2026: VERAXA Biotech AG, part of Xlife Sciences AG, cleared a significant hurdle at its recent Extraordinary General Meeting. An overwhelming 99.57% of shareholders voted in favor of a merger involving VERAXA Biotech AG, Veraxa Biotech Holding AG, and Voyager Acquisition Corp. This endorsement signals robust confidence in VERAXA's strategic plans, setting the path toward a NASDAQ listing under the ticker symbol "VRXA."

CEO Dr. Christoph Antz expressed gratitude for the shareholder support, emphasizing the company's commitment to developing innovative cancer therapies. Oliver R. Baumann, CEO of Xlife Sciences AG, highlighted the merger's strategic importance, pointing to VERAXA's strong technological and scientific foundation.

The merger, expected to be finalized following Voyager’s shareholder approval, aligns VERAXA for greater market presence. Further information is available via VERAXA’s and Voyager’s official channels.